 Indias drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Sciences experimental COVID-19 treatment remdesivir, the Indian pharmaceutical company said on Sunday. The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees 66-79 for a 100 milligram dose, Hetero said. Indias Cipla Ltd has also received approval from the Drug Controller General of India DGCI to manufacture and market the drug, according to a report in Indian Express. 